INDEMNIFICATION AGREEMENTIndemnification Agreement • August 29th, 2019 • Viela Bio, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this day of , 20 , by and between Viela Bio, Inc. a Delaware corporation (the “Company”), and (“Indemnitee”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 29th, 2019 • Viela Bio, Inc. • Pharmaceutical preparations • Maryland
This Employment Agreement (this “Agreement”), entered into as of August 28, 2019 is made and entered into by and between Viela Bio, Inc. (“Company”) and Aaron Ren (“Employee”).
LICENSE AND COLLABORATION AGREEMENTLicense and Collaboration Agreement • August 29th, 2019 • Viela Bio, Inc. • Pharmaceutical preparations
This License and Collaboration Agreement (the “Agreement”), dated as of the last signature hereunder (the “Effective Date”), is by and between Viela Bio, Inc., a company organized and existing under the laws of Delaware, United States of America (“Viela”), and Hansoh Pharmaceutical Group Company Limited, a company organized and existing under the laws of Cayman Islands (“Hansoh”). Viela and Hansoh are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
BIOWA/LONZA SUBLICENSE AGREEMENT between MEDIMMUNE, LLC and VIELA BIO, INC. Dated as of February 23, 2018Sublicense Agreement • August 29th, 2019 • Viela Bio, Inc. • Pharmaceutical preparations • New York
This BioWa/Lonza Agreement (this “Agreement”) is made and entered into as of February 23, 2018 (the “Effective Date”) by and between MedImmune, LLC, a Delaware corporation, whose registered office is at One MedImmune Way, Gaithersburg, Maryland 20878 (and which is a member of the AstraZeneca group of companies) (“MedImmune”) and Viela Bio, Inc., a Delaware corporation (“Spinco”). MedImmune and Spinco are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
MASTER SUPPLY AND DEVELOPMENT SERVICES AGREEMENT between ASTRAZENECA UK LIMITED and VIELA BIO, INC. DATE: Febuaruy 23, 2018Master Supply and Development Services Agreement • August 29th, 2019 • Viela Bio, Inc. • Pharmaceutical preparations • New York
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
COMMERCIAL SUPPLY AGREEMENT by and between ASTRAZENECA PHARMACEUTICALS LP and VIELA BIO, INC. DATED AS OF APRIL 4, 2019Commercial Supply Agreement • August 29th, 2019 • Viela Bio, Inc. • Pharmaceutical preparations • New York
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
SUPPLEMENTAL AGREEMENTSupplemental Agreement • August 29th, 2019 • Viela Bio, Inc. • Pharmaceutical preparations • New York
SBIBT and Viela Bio agree that, effective as of the Assignment Date, the address of each Party under Section 12.3 of the License Agreement shall be changed to the following:
MRC PAYMENT AGREEMENT (MEDI-7734) between MEDIMMUNE LIMITED And VIELA BIO, INC. Dated as of February 23, 2018MRC Payment Agreement • August 29th, 2019 • Viela Bio, Inc. • Pharmaceutical preparations • England and Wales
This MRC Payment Agreement (this “Agreement”) is made by way of a deed and entered into as of February 23, 2018 (the “Effective Date”) by and between MedImmune Limited, a company formed and registered under the laws of England and Wales, whose registered office is at Milstein Building, Granta Park, Cambridge, CB21 6GH (and which is a member of the AstraZeneca group of companies) (“MedImmune”) and Viela Bio, Inc., a Delaware corporation (“Spinco”). MedImmune and Spinco are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LONZA SUBLICENSE AGREEMENT between MEDIMMUNE, LLC and VIELA BIO, INC. Dated as of February 23, 2018Sublicense Agreement • August 29th, 2019 • Viela Bio, Inc. • Pharmaceutical preparations • New York
This Lonza Sublicense Agreement (this “Agreement”) is made and entered into as of February 23, 2018 (the “Effective Date”) by and between MedImmune, LLC, a Delaware corporation, whose registered office is at One MedImmune Way, Gaithersburg, Maryland 20878 (and which is a member of the AstraZeneca group of companies) (“MedImmune”) and Viela Bio, Inc., a Delaware corporation (“Spinco”). MedImmune and Spinco are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ASSET PURCHASE AGREEMENT BY AND BETWEEN MEDIMMUNE, LLC, MEDIMMUNE LIMITED, ASTRAZENECA COLLABORATION VENTURES, LLC, AND VIELA BIO, INC. DATED AS OF FEBRUARY 23, 2018Asset Purchase Agreement • August 29th, 2019 • Viela Bio, Inc. • Pharmaceutical preparations • New York
This ASSET PURCHASE AGREEMENT is entered into as of February 23, 2018 (this “Agreement”), by and between MEDIMMUNE, LLC, a Delaware limited liability company (“Medi LLC”), MEDIMMUNE LIMITED, a United Kingdom company (“Medi Ltd”), and ASTRAZENECA COLLABORATION VENTURES, LLC, a Delaware limited liability company (“AZCV”), and VIELA BIO, INC., a Delaware corporation (“Spinco”). Each of Medi LLC, Medi Ltd and AZCV are sometimes referred to herein individually as an “AZ Party” and collectively as the “AZ Parties.” Each of the AZ Parties and Spinco are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used herein and not otherwise defined shall have the meanings set forth in Exhibit A.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 29th, 2019 • Viela Bio, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of September 21, 2004 (“Effective Date”), is between the Dana-Farber Cancer Institute, Inc., a Massachusetts non-profit organization having a principal place of business at 44 Binney Street, Boston, Massachusetts, 02115 (“DFCI”), and Cellective Therapeutics, Inc, a Delaware corporation having a principal place of business at 100 Capitola Drive, Suite 103, Durham, North Carolina 27713 (“Licensee”).
